315 related articles for article (PubMed ID: 30054698)
1. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.
Antwi K; Fani M; Heye T; Nicolas G; Rottenburger C; Kaul F; Merkle E; Zech CJ; Boll D; Vogt DR; Gloor B; Christ E; Wild D
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2318-2327. PubMed ID: 30054698
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.
Luo Y; Pan Q; Yao S; Yu M; Wu W; Xue H; Kiesewetter DO; Zhu Z; Li F; Zhao Y; Chen X
J Nucl Med; 2016 May; 57(5):715-20. PubMed ID: 26795291
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
Wild D; Antwi K; Fani M; Christ ER
J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073
[TBL] [Abstract][Full Text] [Related]
4. Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging.
Antwi K; Hepprich M; Müller NA; Reubi JC; Fani M; Rottenburger C; Nicolas G; Kaul F; Christ ER; Wild D
Clin Nucl Med; 2020 Sep; 45(9):e386-e392. PubMed ID: 32558709
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.
Christ E; Wild D; Ederer S; Béhé M; Nicolas G; Caplin ME; Brändle M; Clerici T; Fischli S; Stettler C; Ell PJ; Seufert J; Gloor B; Perren A; Reubi JC; Forrer F
Lancet Diabetes Endocrinol; 2013 Oct; 1(2):115-22. PubMed ID: 24622317
[TBL] [Abstract][Full Text] [Related]
6. [(68)Ga-exendin-4 PET-CT for the localization of occult insulinomas: a prospective cohort study].
Luo YP; Pan QQ; Li F; Yu M; Xing XP; Zhang TP; Zhao YP
Zhonghua Wai Ke Za Zhi; 2018 Nov; 56(11):837-842. PubMed ID: 30392304
[No Abstract] [Full Text] [Related]
7. 68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1.
Antwi K; Nicolas G; Fani M; Heye T; Pattou F; Grossman A; Chanson P; Reubi JC; Perren A; Gloor B; Vogt DR; Wild D; Christ E
J Clin Endocrinol Metab; 2019 Dec; 104(12):5843-5852. PubMed ID: 31298706
[TBL] [Abstract][Full Text] [Related]
8. Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.
Antwi K; Fani M; Nicolas G; Rottenburger C; Heye T; Reubi JC; Gloor B; Christ E; Wild D
J Nucl Med; 2015 Jul; 56(7):1075-8. PubMed ID: 25999434
[TBL] [Abstract][Full Text] [Related]
9. Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys
Senica K; Tomazic A; Skvarca A; Kolenc Peitl P; Mikolajczak R; Hubalewska-Dydejczyk A; Lezaic L
Mol Imaging Biol; 2020 Feb; 22(1):165-172. PubMed ID: 31098984
[TBL] [Abstract][Full Text] [Related]
10. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
Joosten L; Frielink C; Jansen TJP; Lobeek D; Andreae F; Konijnenberg M; Heskamp S; Gotthardt M; Brom M
Mol Pharm; 2023 Jul; 20(7):3519-3528. PubMed ID: 37265006
[TBL] [Abstract][Full Text] [Related]
11. Innovative imaging of insulinoma: the end of sampling? A review.
Christ E; Antwi K; Fani M; Wild D
Endocr Relat Cancer; 2020 Apr; 27(4):R79-R92. PubMed ID: 31951592
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.
Brom M; Oyen WJ; Joosten L; Gotthardt M; Boerman OC
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1345-55. PubMed ID: 20111963
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 receptor imaging for localization of insulinomas.
Christ E; Wild D; Forrer F; Brändle M; Sahli R; Clerici T; Gloor B; Martius F; Maecke H; Reubi JC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4398-405. PubMed ID: 19820010
[TBL] [Abstract][Full Text] [Related]
14. [
Zhang P; Zhao Z; Zhang L; Wu W; Xu Y; Pan D; Wang F; Yang M
Nucl Med Biol; 2019; 74-75():19-24. PubMed ID: 31450071
[TBL] [Abstract][Full Text] [Related]
15. Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report.
Eriksson O; Velikyan I; Selvaraju RK; Kandeel F; Johansson L; Antoni G; Eriksson B; Sörensen J; Korsgren O
J Clin Endocrinol Metab; 2014 May; 99(5):1519-24. PubMed ID: 24512490
[TBL] [Abstract][Full Text] [Related]
16. Volume Replacement Fluid Demarks Benign Insulinoma With 68Ga-DOTA-Exendin-4 PET/CT.
Antwi K; Nicolas G; Fani M; Christ E; Wild D
Clin Nucl Med; 2019 May; 44(5):e347-e348. PubMed ID: 30889001
[TBL] [Abstract][Full Text] [Related]
17. Utility of
Kalff V; Iravani A; Akhurst T; Pattison DA; Eu P; Hofman MS; Hicks RJ
Intern Med J; 2021 Oct; 51(10):1657-1664. PubMed ID: 33314504
[TBL] [Abstract][Full Text] [Related]
18. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.
Wild D; Wicki A; Mansi R; Béhé M; Keil B; Bernhardt P; Christofori G; Ell PJ; Mäcke HR
J Nucl Med; 2010 Jul; 51(7):1059-67. PubMed ID: 20595511
[TBL] [Abstract][Full Text] [Related]
19. Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
Kaeppeli SAM; Jodal A; Gotthardt M; Schibli R; Béhé M
Mol Pharm; 2019 Sep; 16(9):3760-3769. PubMed ID: 31393738
[TBL] [Abstract][Full Text] [Related]
20. Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT.
Michalski K; Laubner K; Stoykow C; Omrane MA; Maecke HR; Seufert J; Goetz C; Meyer PT; Ruf J
Clin Nucl Med; 2020 Jul; 45(7):519-524. PubMed ID: 32453080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
